Brexit Declaration Offers Scant Comfort On Future UK-EU Regulatory Links
Executive Summary
EU leaders have endorsed the “political declaration” outlining the aspirations for the future relationship between the UK and the EU after Brexit, together with the much larger withdrawal deal. The life sciences industry will be disappointed that in the drug regulatory area the political declaration contains little beyond an aspiration for “possible” cooperation between the UK drug regulator and the European Medicines Agency.
You may also be interested in...
UK Smooths Clinical Trial Pathway To Reassure Companies With Brexit Jitters
The UK is revising its clinical trial processes to align them with the new EU Clinical Trials Regulation so that companies can seek authorization just as easily in the UK as in other EU member states, irrespective of the situation after Brexit.
Health Must Be At Center Of Post-Brexit Relationship, Say Industry & NHS Bodies
UK industry and National Health Service bodies say that the “political declaration” on the future UK-EU relationship fails to address key public health issues such as regulatory cooperation, collaboration in science and innovation, and tackling counterfeit medicines.
UK Pharma Takes Hope From Draft Brexit Deal But Uncertainty Reigns
The Brexit deal agreed by UK ministers brings little certainty for the life sciences sector. Moreover, the related and unprecedented political instability means that its final approval is far from guaranteed.